Lumit® Immunoassays Cellular Systems: Illuminating the Way to Faster, Easier Signaling Pathway Analysis
What you will learn:
- Simple, add-and-read protocols with no sample transfers, washes or dilutions
- The broad dynamic range of the Lumit® assay
- Example applications for several common signaling pathways, including NF-κB
Summary
Signaling pathway activation leads to a multitude of cellular responses, including enzyme activity modulation, gene expression and protein translocation or degradation. Reversible protein phosphorylation is a common mechanism that transduces the signal from an upstream activation event to downstream cellular responses. Detecting cellular phosphorylation events is often performed using heterogeneous methods, such as Western blotting and ELISA-based techniques. Western blotting requires separation and transfer steps, while ELISAs involve lots of procedural steps. In addition, both methods often require overnight incubations. Join us to learn how the Lumit® Immunoassay Cellular Systems can simplify your workflow and yield results faster!
Speakers
Hicham Zegzouti, PhD
Senior Research Scientist
Dr. Hicham Zegzouti is a Senior Research Scientist in the Promega Assay Design-R&D. His group develops Assay technologies to interrogate diverse enzyme activities and cellular pathways (kinases, glycosyltransferases, and other drug targets). Dr. Zegzouti received his PhD in 1997 from the National Polytechnic Institute of Toulouse, France. Prior to joining Promega, he was a postdoctoral researcher in Molecular, Cell and Developmental Biology at UC-Los Angeles studying auxin hormone signaling in an Arabidopsis plant model. His work focused on the identification and characterization of AGC kinase family and its regulation during plant development. Dr. Zegzouti has authored 25 journal articles and book chapters, co-edited a methods book and is an inventor for several patents.
Senior Research Scientist
Brian Hwang is a Senior Research Scientist in the Assay Design Division of Research & Development at Promega Corporation. He is interested in the molecular processes that regulate cellular signaling in diseases such as cancer and metabolic diseases. He develops Lumit® Immunoassay to investigate cell signaling pathways at Promega. Prior to joining Promega, he was a postdoctoral researcher in Department of Oncology at the University of Wisconsin-Madison, studying DNA damage-mediated NF-κB activation. His work focused on identifying a cell signaling mechanism by which cancer cells gain resistance against genotoxic anti-cancer drug.
Brian received his Ph.D. in 2009 from Indiana University, studying a role of pyruvate dehydrogenase kinase 4 (PDHK4) in the induction of hepatic steatosis in diet-induced diabetic and obese mice model. He has authored 15 journal articles and 1 filed patent. He received The DeVault PhD student fellowship of the Diabetes and Obesity Training award from Indiana University School of Medicine Diabetes Center in 2004 and 2005.